[Expression of lung resistant-related protein in ovarian cancer and its clinical significance].
OBJECTIVE
It was reported that there was negative correlation between the over-expression of lung resistant-related protein (LRP) and the sensitivity of cisplatin and cyclophosphamide. Also it was reported that the over-expression of LRP could predict the chemosensitivity and prognosis of ovarian cancer, and it was an independent index of remission and exist period. This study was designed to investigate the function of LRP in cisplatin resistance and the relationship with prognosis of ovarian cancer by combining with the chemosensitivity test.


METHODS
1. ATP bioluminescence assay was used to determine the drug sensitivity of 50 specimens of fresh epithelial ovarian cancer tissues. Patients' responses were obtained by accepted clinical assessment methods after three treatment courses. 2. Expression of LRP in 50 paraffin specimens of ovarian cancer was determined using immunohistochemistry.


RESULTS
1. The non-overexpression of LRP in ovarian cancer was 24%, and the overexpression of LRP was 76%. 2. The non-overexpression of LRP in the cisplatin-sensitive ovarian cancer was 10/12(75%), while in the cisplatin-resistance was 3/12(25%). There was no significantly different. 3. The over-expression of LRP was increased in advanced and low grade ovarian cancer, and there was significantly different.


CONCLUSIONS
Expression of LRP is related to stages, grades, and chemosensitivity of ovarian cancer, and it could become an index of screening drug and judging the prognosis of patients.
Qian
Xiao-lei
XL
Department of Obstetrics and Gynecology, Second University Hospital of West China, Sichuan University, Chengdu 610041, P. R. China. Lei821@263.net
Peng
Zhi-lan
ZL
Liu
Shan-ling
SL
Wang
He
H
Ni
Jian
J
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000096:biosynthesis; D002945:Cisplatin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D011379:Prognosis; D020394:Vault Ribonucleoprotein Particles / Q000096:biosynthesis*; D000099187:Major Vault Protein
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D002945:Cisplatin; D009363:Neoplasm Proteins; D020394:Vault Ribonucleoprotein Particles; D000099187:Major Vault Protein